France · Source-listed medicine information

France / CIS 60645557

HEXYON, suspension injectable en seringue préremplie

suspension injectable · intramusculaire

Directory source checks passedOriginal source language: French

Source data retrieved: 2026-09-17. Clinical review is not yet available.

Formsuspension injectable
Routeintramusculaire
Ingredient entries9
CountryFrance

Product identity

At a glance

Authorisation holder
SANOFI WINTHROP INDUSTRIE
Authorisation status
Autorisation active
Market status
Commercialisée
Country
France
Source reference
CIS 60645557

Reported market status does not confirm current pharmacy stock.

From the official composition record

Ingredients & strength

Source entries are shown individually. An active substance (SA) and its reference moiety (FT) may describe the same ingredient; do not add their strengths together.

Source composition entries for HEXYON, suspension injectable en seringue préremplie
IngredientStrength / referenceSource role
ANATOXINE DIPHTÉRIQUE suspensionsupérieur ou égal à 20 UI0,50 mlSAGroup 1
ANATOXINE TÉTANIQUE suspensionsupérieur ou égal à 40 UI0,50 mlSAGroup 2
VIRUS POLIOMYÉLITIQUE SOUCHE MEF-1 DE TYPE 2 INACTIVÉ suspension8 U.D0,50 mlSAGroup 6
VIRUS POLIOMYÉLITIQUE SOUCHE SAUKETT DE TYPE 3 INACTIVÉ suspension32 U.D0,50 mlSAGroup 7
ANTIGÈNE DE SURFACE DE L'HÉPATITE B RECOMBINANT suspension10 microgrammes0,50 mlSAGroup 8
VIRUS POLIOMYELITIQUE SOUCHE MAHONEY DE TYPE 1 INACTIVÉ suspension40 U.D0,50 mlSAGroup 5
POLYOSIDE HAEMOPHILUS INFLUENZAE TYPE B CONJUGUÉ À L'ANATOXINE TÉTANIQUEsuspension12 microgrammes0,50 mlSAGroup 9
ANTIGÈNE COQUELUCHEUX : HÉMAGGLUTININE FILAMENTEUSE suspension25 microgrammes0,50 mlSAGroup 4
ANTIGÈNE COQUELUCHEUX : ANATOXINE suspension25 microgrammes0,50 mlSAGroup 3

Pack references

Presentations (2)

1 seringue(s) préremplie(s) en verre de 0,5 ml avec 1 aiguille(s)

CIP13 3400927350078

Présentation active · Déclaration de commercialisation
1 seringue(s) préremplie(s) en verre de 0,5 ml avec 2 aiguille(s)

CIP13 3400927350368

Présentation active · Déclaration d'arrêt de commercialisation

From the French medicines authority

Official documents

The official product entry provides access to the patient leaflet and professional product information when available. Documents are in French and availability varies by medicine.

Open the official product entryBDPM · CIS 60645557 · Opens in a new tab

Check the medicine name, strength and form against your pack. The authority’s current documents may be newer than the catalogue snapshot shown here.

Where this information comes from

Sources & dates

Base de données publique des médicaments (BDPM), France. Retrieval dates record when we obtained the source files; they are not clinical review dates or a guarantee of current stock.

Source files and their retrieval dates
Source fileRetrievedSource file modified
fr_products.txtNot supplied
fr_composition.txtNot supplied
fr_packs.txtNot supplied

Directory source checks cover the factual catalogue record.Molindra clinical guidance has not yet been reviewed or published for this medicine.

Our sources and review process →